Navigation Links
Enobia Pharma Presents PreClinical Data Showing ENB-0040 Significantly Improved Survival and Healed Skeletal Manifestations of Severe Hypophosphatasia in Mice
Date:9/15/2008

MONTREAL, Sept. 15 /PRNewswire/ -- Enobia Pharma, an emerging biotech company focused on developing novel therapeutics for serious bone disorders, presented pre-clinical data demonstrating that its enzyme replacement therapy (ERT) for hypophosphatasia appears to heal bones that have already been severely weakened by the disease. Earlier pre-clinical data showed that ERT with Enobia's product ENB-0040, significantly increases survival and prevents bone hypomineralization associated with hypophosphatasia, a rare genetic bone disease.

Dr. Isabelle Lemire presented the positive results from several pre-clinical studies of ENB-0040 at the American Society of Bone and Mineral Research's 30th Annual Meeting in Montreal, Quebec on September 13th. Results of efficacy, safety and toxicology pre-clinical studies supported the initiation of clinical trials, announced last month.

"We are extremely pleased to see evidence that enzyme replacement therapy with ENB-0040 may help repair skeletal damage caused by hypophosphatasia, as well as prevent the onset of dangerous bone hypomineralization," said Dr. Lemire, Associate Director of Non Clinical Studies, Enobia Pharma. "We look forward to advancing our clinical studies and confirming these results in patients with this deadly disease who currently have no approved treatment options."

The treatment data were not available at the time of the original publication of Enobia's pre-clinical studies in the Journal of Bone and Mineral Research [June 2008:23:777-787]. In these studies, subcutaneous administration of ENB-0040 was shown to significantly improve survival and prevent skeletal and dental manifestations of the disease.

Doctors at the University of Manitoba, Winnipeg dosed the first patient in Enobia's clinical program investigating ERT with ENB-0040 as a treatment of this rare and often crippling genetic bone disorder in August.

Dr. Thomas Loisel, Associate Director of Process Development
'/>"/>

SOURCE Enobia Pharma
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Enobia Pharma Raises $40.1 Million Series B Financing
2. Zenobia Therapeutics, Inc. Begins Operations as a Fragment-Based Lead Discovery Company
3. Zenobia Therapeutics, Inc. Receives Michael J. Fox Foundation for Parkinsons Research Award for Work on PD-implicated Protein LRRK2
4. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.
5. Pharmatek Adds Cytotoxic and High-Potent Drug Development Capabilities to San Diego Laboratory
6. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
7. Skystar Bio-Pharmaceutical Announces Second Quarter 2007 Results
8. Proceedings to Affirm Merger Between PharmAthene and Healthcare Acquisition Corp Initiated in Delaware Chancery Court
9. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
10. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
11. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... 2014  Orexigen Therapeutics, Inc. (Nasdaq: OREX ... List of Outstanding Issues (LOI) from the European Medicines ... for the NB32 Marketing Authorization Application (MAA). NB32 (naltrexone ... drug candidate being evaluated for weight loss. ... point were adequately addressed by the Company based in ...
(Date:7/30/2014)... July 30, 2014 Researchers often use ... biology, but such devices can do much more ... As such, researchers have looked to patterned assemblies ... metabolic engineering to characterize – and potentially ... devices are envisioned to recreate animal and human ...
(Date:7/30/2014)... 2014  AtheroNova Inc. (OTCBB: AHRO), a biotech ... compounds to safely regress atherosclerotic plaque and improve ... partner, CardioNova, has accomplished first dosing of subjects ... lead compound, AHRO-001.  This Phase 1b trial will ... safety trial completed in February 2014, in which ...
(Date:7/30/2014)... (PRWEB) July 30, 2014 NCERC ... Athmanathan will present his findings on corn stover ... conference this week in Washington, D.C. , ... Energy conference is a testament to the success ... Caupert said. “Thanks to the foresight and vision ...
Breaking Biology Technology:Orexigen Receives CHMP Day 180 List of Outstanding Issues 2Orexigen Receives CHMP Day 180 List of Outstanding Issues 3UMD Researchers Bridge Gap between Microelectronics, Biological Systems 2UMD Researchers Bridge Gap between Microelectronics, Biological Systems 3UMD Researchers Bridge Gap between Microelectronics, Biological Systems 4AtheroNova Announces Milestone with Initiation of Phase 1b Clinical Trial of AHRO-001 2AtheroNova Announces Milestone with Initiation of Phase 1b Clinical Trial of AHRO-001 3AtheroNova Announces Milestone with Initiation of Phase 1b Clinical Trial of AHRO-001 4NCERC at SIUE Researcher Takes Stage at Department of Energy Conference 2NCERC at SIUE Researcher Takes Stage at Department of Energy Conference 3
... HILL, England, September 1 , With some ... to start the,new school year, new guidance from ... looks set to revolutionise the way children,manage their ... by greater access to insulin pump therapy. The ...
... treatment of HIV-positive individuals with American Biotech ... improvement in the condition of the subjects after ... nanosilver particles can block entry of the ... ALPINE, UT, Aug. 29 /PRNewswire-FirstCall/ - American Biotech ...
... Corporation,(Nasdaq: PARS ) today announced that effective ... Israel, and manage those activities currently,based in Rehovot ... New,Jersey., The research programs in Israel are ... development of PRS-639,058 for,neuropathic pain. Additionally the Company ...
Cached Biology Technology:British School Kids With Diabetes Gain First Time Freedom From Injections With New Insulin Pump Guidelines 2British School Kids With Diabetes Gain First Time Freedom From Injections With New Insulin Pump Guidelines 3British School Kids With Diabetes Gain First Time Freedom From Injections With New Insulin Pump Guidelines 4Preliminary Report of American Biotech Labs HIV Study Featured in Inaugural Issue of Journal of the Science of Healing Outcomes 2Pharmos Corporation Announces That it Will Cease Operations in Israel 2
(Date:7/30/2014)... changing climate threaten some of the world,s most ... establish seed collections to save the seeds in ... some genetic diversity., For decades, these seed collections ... a one-size-fits-all approach for how many seeds to ... regardless of species, pollination mode, growth habitat and ...
(Date:7/30/2014)... they eat, the Food and Drug Administration (FDA) earlier ... label found on nearly every food product in the ... (C&EN), the weekly news magazine of the American ... fight that has ensued. , Britt Erickson, a senior ... Facts label has remained largely the same for two ...
(Date:7/30/2014)... from Wayne State University,s College of Engineering recently ... Foundation for the project, "Nanoparticle-directed synthesis of organic ... Foundation, nanotechnology is the creation and utilization of ... and functions. A major bottleneck in scaling up ... connect different functional materials into one device. A ...
Breaking Biology News(10 mins):Saving seeds the right way can save the world's plants 2NSF grant to Wayne State supports new concept for manufacturing nanoscale devices 2
... amorous midshipman fish to the strains of a Puccini aria ... neural circuitry that led to the human love song not ... of vertebrates was likely laid down hundreds of millions of ... By mapping the developing brain cells in newly hatched midshipman fish ...
... for food service and salad mixes is an increasingly ... perishable, and the cutting required in processing further shortens ... fresh produce in semipermeable plastic films extends shelf life ... modified-atmosphere (MA) packaging for lettuce and certain salad greens ...
... joining forces to conceptualize, develop and bring to reality ... care through UC San Diego,s new Institute of Engineering ... to repair damaged hearts, and scarless surgery techniques are ... with the new Institute leading the way. "As ...
Cached Biology News:From humming fish to Puccini: Vocal communication evolved with ancient species 2Good breeding increases shelf life 2UC San Diego launches Institute of Engineering in Medicine to accelerate health care tech 2UC San Diego launches Institute of Engineering in Medicine to accelerate health care tech 3
...
... Western Blot Strong Antibody Stripping Solution is ... blots that have been developed with chemiluminescence ... is not recommended for stripping colorimetric substrates ... not possible to effectively remove substrates that ...
... Liquid. 100 ml supplied as a ... remove antibodies from membrane-bound proteins without ... stripping chemiluminescent or radioisotopic signals from ... Western blots. Supplied as a 5X ...
... is specifically designed for two-dimensional electrophoresis ... four proteins in this marker have ... pattern across a 2D gel. The ... Mol wt: 17,000-89,000 ...
Biology Products: